XML 35 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Collaboration and Other Agreements - I-Mab Biopharma (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Jul. 31, 2019
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Jul. 09, 2019
Collaboration And Other Agreements [Line Items]              
Revenues   $ 20,257,000 $ 10,593,000 $ 33,939,000 $ 20,255,000    
Deferred revenue, current   9,267,000   9,267,000   $ 10,700,000  
Deferred revenue, net of current portion   6,819,000   6,819,000   9,153,000  
I-Mab | I-Mab Biopharma Collaboration and License Agreement              
Collaboration And Other Agreements [Line Items]              
Non-refundable upfront payment $ 15,000,000.0            
Potential development and regulatory milestone payments under agreement             $ 135,000,000.0
Estimated variable consideration $ 1,000,000.0            
Revenues   1,400,000 $ 0 2,500,000 $ 0    
Deferred revenue   11,100,000   11,100,000   13,500,000  
Deferred revenue, current   4,300,000   4,300,000   4,400,000  
Deferred revenue, net of current portion   $ 6,800,000   $ 6,800,000   $ 9,100,000  
I-Mab | I-Mab Biopharma Collaboration and License Agreement | Maximum              
Collaboration And Other Agreements [Line Items]              
Potential proceeds from royalties (percent) 20.00%